Literature DB >> 9126207

Intravenous-to-oral antibiotic switch therapy. A cost-effective approach.

B A Cunha1.   

Abstract

Every attempt should be made to switch hospitalized infectious-disease patients from intravenous to oral antibiotic therapy as soon as clinical improvement makes it possible. In addition to tremendous cost savings, the advantages of oral therapy are impressive and include a decrease in the number of nosocomial infections, shorter length of hospital stay, and lower incidence of intravenous-line infections. The main barrier to the acceptance of switch therapy is a lack of understanding of its efficacy, safety, and cost advantages. The wide-scale institution of managed care has resulted in the dawning of the era of oral antimicrobial therapy. Everything from infective endocarditis in intravenous drug abusers to neuroborreliosis may be treated effectively by the oral route.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126207     DOI: 10.3810/pgm.1997.04.199

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Authors:  S C Chien; M C Rogge; L G Gisclon; C Curtin; F Wong; J Natarajan; R R Williams; C L Fowler; W K Cheung; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

2.  Treatment-Related Complications in Children Hospitalized With Disseminated Lyme Disease.

Authors:  Christine Chang; Kristen A Feemster; Susan Coffin; Lori K Handy
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

3.  Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model.

Authors:  Samantha J Eells; Kiran Bharadwa; James A McKinnell; Loren G Miller
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

Review 4.  Switch over from intravenous to oral therapy: A concise overview.

Authors:  Jissa Maria Cyriac; Emmanuel James
Journal:  J Pharmacol Pharmacother       Date:  2014-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.